No connection

Search Results

AMS

BEARISH
$1.33 Live
American Shared Hospital Services · AMEX
Target $4.0 (+199.6%)
$1.25 52W Range $3.11

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$8.81M
P/E
N/A
ROE
-9.4%
Profit margin
-5.5%
Debt/Equity
0.78
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
AMS exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity position with a current ratio of 0.76. The company is experiencing a systemic decline, evidenced by a -14.80% YoY revenue contraction and a disastrous -200% YoY EPS growth. Despite a low Price-to-Book ratio of 0.37, the stock is in a technical freefall (0/100 trend) and consistently misses earnings estimates by wide margins. The combination of negative profitability and shrinking top-line growth suggests a value trap rather than a value opportunity.

Key Strengths

Positive Gross Margin (38.31%)
Low Price-to-Book ratio (0.37)
Low Price-to-Sales ratio (0.31)
Manageable Debt/Equity ratio (0.78) relative to sector average
Forward P/E suggests potential recovery if earnings stabilize

Key Risks

Severe liquidity risk (Current Ratio 0.76 < 1.0)
Negative revenue growth (-14.80% YoY)
Consistent and massive earnings misses (Recent surprise -550%)
Extreme price depreciation (-51.6% over 1 year)
Micro-cap volatility and low market capitalization ($0.01B)
AI Fair Value Estimate
Based on comprehensive analysis
$0.85
-36.3% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
15
Weak
Value
40
Future
10
Past
5
Health
20
Dividend
0
AI Verdict
High Risk / Value Trap
Key drivers: Piotroski F-Score 2/9, Negative Revenue Growth, Liquidity Crisis, Bearish Technicals
Confidence
90%
Value
40/100

Trades at a deep discount to book value, but fundamentals do not support the valuation.

Positives
  • P/B of 0.37
  • P/S of 0.31
Watchpoints
  • Negative earnings render P/E metrics unreliable
  • Lack of Graham Number baseline
Future
10/100

Growth metrics are aggressively negative across all timeframes.

Positives
No standout positives identified.
Watchpoints
  • Revenue declining YoY and Q/Q
  • EPS growth at -200%
Past
5/100

Long-term and short-term price performance is overwhelmingly bearish.

Positives
No standout positives identified.
Watchpoints
  • 1Y return -51.6%
  • 5Y return -46.8%
  • Consistent earnings misses
Health
20/100

F-Score indicates weak financial health; liquidity ratios suggest inability to cover short-term obligations.

Positives
  • Debt/Equity lower than sector average
Watchpoints
  • Piotroski F-Score 2/9
  • Current Ratio 0.76
  • Quick Ratio 0.71
Dividend
0/100

Non-dividend paying stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.33
Analyst Target
$4.0
Upside/Downside
+199.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for AMS and closest competitors.

Updated 2026-04-23
AMS
American Shared Hospital Services
Primary
5Y
-46.8%
3Y
-52.8%
1Y
-51.6%
6M
-41.2%
1M
-29.5%
1W
-10.7%
TNO
Tenon Medical, Inc.
Peer
5Y
-100.0%
3Y
-99.5%
1Y
-28.8%
6M
-37.7%
1M
-0.6%
1W
-2.7%
XWE
XWELL, Inc.
Peer
5Y
-96.0%
3Y
-79.6%
1Y
+48.0%
6M
+18.8%
1M
-15.6%
1W
+9.6%
NOT
Inotiv, Inc.
Peer
5Y
-98.8%
3Y
-95.0%
1Y
-84.2%
6M
-82.6%
1M
-31.9%
1W
-2.0%
SIL
Silo Pharma, Inc.
Peer
5Y
-96.0%
3Y
-78.0%
1Y
-52.1%
6M
-8.0%
1M
+60.9%
1W
+16.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
3.34
PEG Ratio
N/A
P/B Ratio
0.37
P/S Ratio
0.31
EV/Revenue
1.09
EV/EBITDA
8.29
Market Cap
$8.81M

Profitability

Profit margins and return metrics

Profit Margin -5.53%
Operating Margin -13.98%
Gross Margin 38.31%
ROE -9.45%
ROA -2.18%

Growth

Revenue and earnings growth rates

Revenue Growth -14.8%
Earnings Growth N/A
Q/Q Revenue Growth -14.79%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.78
Moderate
Current Ratio
0.76
Weak
Quick Ratio
0.71
Poor
Cash/Share
$0.52

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
11.7%
Op. Margin
-14.0%
Net Margin
-8.2%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.16x
Operating CF
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
-182%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14
$N/A
2026-03-31
$-0.09
-550.0% surprise
2025-11-13
$N/A
2025-08-13
$-0.04
+42.9% surprise

Healthcare Sector Comparison

Comparing AMS against 528 companies in the Healthcare sector (28 bullish, 156 neutral, 344 bearish)
Return on Equity (ROE)
-9.45%
This Stock
vs
-92.94%
Sector Avg
-89.8% (Below Avg)
Profit Margin
-5.53%
This Stock
vs
-16.56%
Sector Avg
-66.6% (Weaker)
Debt to Equity
0.78
This Stock
vs
2.75
Sector Avg
-71.5% (Less Debt)
Revenue Growth
-14.8%
This Stock
vs
131.76%
Sector Avg
-111.2% (Slower)
Current Ratio
0.76
This Stock
vs
4.62
Sector Avg
-83.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

STACHOWIAK RAYMOND C
Officer, Director and Beneficial Owner
Stock Award
2026-03-26
100,000 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
FORM 8-K
2026-03-31

AMS filed an 8-K on March 31, 2026, likely to report its first-quarter financial results.

10-K
FORM 10-K
2026-03-31

AMS filed its Form 10-K on March 31, 2026. The provided excerpts consist of the filing's table of contents and standard forward-looking statement disclosures, with no specific financial highlights or risk factors detailed in the text.

8-K
FORM 8-K
2026-03-19
8-K
FORM 8-K
2026-01-02

AMS filed a Form 8-K on January 2, 2026, likely reporting year-end corporate governance updates or executive appointments.

8-K
FORM 8-K
2025-12-16
10-Q
FORM 10-Q
2025-11-14

AMS submitted its Form 10-Q on November 14, 2025, reporting no material changes to the risk factors previously disclosed in its Annual Report for the year ended December 31, 2024. Specific financial highlights were not provided in the available filing excerpts.

8-K
FORM 8-K
2025-11-13

AMS filed an 8-K on November 13, 2025, likely to announce its third-quarter financial results.

10-Q
FORM 10-Q
2025-08-13

AMS filed its Form 10-Q on August 13, 2025, reporting no material changes to the risk factors previously disclosed in its Annual Report for the year ended December 31, 2024. Specific financial highlights were not provided in the available excerpts.

8-K
FORM 8-K
2025-08-13

AMS likely filed this 8-K to announce its second-quarter financial results for 2025.

8-K/A
FORM 8-K/A
2025-07-02
8-K
FORM 8-K
2025-07-02

AMS filed an 8-K on July 2, 2025, likely to announce its second-quarter financial results.

8-K
FORM 8-K
2025-06-09
10-Q
FORM 10-Q
2025-05-15
8-K
FORM 8-K
2025-05-15
DEF 14A
FORM DEF 14A
2025-04-30
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning AMS from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile